Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57


CD7 is expressed on a subset of normal CD34-positive myeloid precursors.

Kriegsmann K, Löffler H, Eckstein V, Schulz R, Kräker S, Braun U, Luft T, Hegenbart U, Schönland S, Dreger P, Krämer A, Ho AD, Müller-Tidow C, Hundemer M.

Eur J Haematol. 2018 May 24. doi: 10.1111/ejh.13100. [Epub ahead of print]


Platelet Count before Peripheral Blood Stem Cell Mobilization Is Associated with the Need for Plerixafor But Not with the Collection Result.

Baertsch MA, Kriegsmann K, Pavel P, Bruckner T, Hundemer M, Kriegsmann M, Ho AD, Goldschmidt H, Wuchter P.

Transfus Med Hemother. 2018 Jan;45(1):24-31. doi: 10.1159/000478911. Epub 2017 Oct 4.


Quantification of number of CD38 sites on bone marrow plasma cells in patients with light chain amyloidosis and smoldering multiple myeloma.

Kriegsmann K, Dittrich T, Neuber B, Awwad MHS, Hegenbart U, Goldschmidt H, Hillengass J, Hose D, Seckinger A, Müller-Tidow C, Ho AD, Schönland S, Hundemer M.

Cytometry B Clin Cytom. 2018 Mar 25. doi: 10.1002/cyto.b.21636. [Epub ahead of print]


Disfiguring facial lesions and loss of sensation.

Hundemer M, Wan CR.

JAAPA. 2018 Jan;31(1):27-29. doi: 10.1097/01.JAA.0000526775.98315.5a.


Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.

Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M.

Oncotarget. 2017 Oct 5;8(58):98200-98214. doi: 10.18632/oncotarget.21516. eCollection 2017 Nov 17.


Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case-based approach.

Baertsch MA, Hundemer M, Hillengass J, Goldschmidt H, Raab MS.

Hematol Oncol. 2018 Feb;36(1):258-261. doi: 10.1002/hon.2473. Epub 2017 Aug 25.


Amyloid in bone marrow smears in systemic light-chain amyloidosis.

Kimmich C, Schönland S, Kräker S, Andrulis M, Ho AD, Mayer G, Dittrich T, Hundemer M, Hegenbart U.

Amyloid. 2017 Mar;24(1):52-59. doi: 10.1080/13506129.2017.1314959. Epub 2017 Apr 23.


Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment.

Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A, Lipp S, Merino J, Prosper F, Emde M, Delon C, Latzko M, Gianotti R, Lüoend R, Murr R, Hosse RJ, Harnisch LJ, Bacac M, Fauti T, Klein C, Zabaleta A, Hillengass J, Cavalcanti-Adam EA, Ho AD, Hundemer M, San Miguel JF, Strein K, Umaña P, Hose D, Paiva B, Vu MD.

Cancer Cell. 2017 Mar 13;31(3):396-410. doi: 10.1016/j.ccell.2017.02.002. Epub 2017 Mar 2.


Performance assessment and benchmarking of autologous peripheral blood stem cell collection with two different apheresis devices.

Wuchter P, Hundemer M, Schmitt A, Witzens-Harig M, Pavel P, Hillengass J, Goldschmidt H, Ho AD, Lisenko K.

Transfus Med. 2017 Feb;27(1):36-42. doi: 10.1111/tme.12367. Epub 2016 Oct 11.


Evolution of a FLT3-TKD mutated subclone at meningeal relapse in acute promyelocytic leukemia.

Bochtler T, Fröhling S, Weichert W, Endris V, Thiede C, Hutter B, Hundemer M, Ho AD, Krämer A.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a001123. doi: 10.1101/mcs.a001123.


Active but not inactive granulomatosis with polyangiitis is associated with decreased and phenotypically and functionally altered CD56(dim) natural killer cells.

Merkt W, Claus M, Blank N, Hundemer M, Cerwenka A, Lorenz HM, Watzl C.

Arthritis Res Ther. 2016 Sep 13;18(1):204. doi: 10.1186/s13075-016-1098-7.


Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17.


Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.

Krämer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M.

Oncoimmunology. 2016 Feb 18;5(5):e1139662. doi: 10.1080/2162402X.2016.1139662. eCollection 2016 May.


Flow cytometry-based characterization of underlying clonal B and plasma cells in patients with light chain amyloidosis.

Lisenko K, Schönland SO, Jauch A, Andrulis M, Röcken C, Ho AD, Goldschmidt H, Hegenbart U, Hundemer M.

Cancer Med. 2016 Jul;5(7):1464-72. doi: 10.1002/cam4.725. Epub 2016 Apr 25.


Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection.

Lisenko K, Pavel P, Bruckner T, Puthenparambil J, Hundemer M, Schmitt A, Witzens-Harig M, Ho AD, Wuchter P.

J Clin Apher. 2017 Feb;32(1):27-34. doi: 10.1002/jca.21463. Epub 2016 Apr 20.


Potential therapeutic targets in plasma cell disorders: A flow cytometry study.

Lisenko K, Schönland S, Hegenbart U, Wallenwein K, Braun U, Mai EK, Hillengass J, Goldschmidt H, Jauch A, Ho AD, Raab M, Hundemer M.

Cytometry B Clin Cytom. 2017 Mar;92(2):145-152. doi: 10.1002/cyto.b.21351. Epub 2016 Feb 3.


Peripheral blood natural killer cell percentages in granulomatosis with polyangiitis correlate with disease inactivity and stage.

Merkt W, Sturm P, Lasitschka F, Tretter T, Watzl C, Saure D, Hundemer M, Schwenger V, Blank N, Lorenz HM, Cerwenka A.

Arthritis Res Ther. 2015 Nov 21;17:337. doi: 10.1186/s13075-015-0851-7.


Immunosuppressive properties of mitomycin C-incubated human myeloid blood cells (MIC) in vitro.

Dittmar L, Mohr E, Kleist C, Ehser S, Demirdizen H, Sandra-Petrescu F, Hundemer M, Opelz G, Terness P.

Hum Immunol. 2015 Jul;76(7):480-7. doi: 10.1016/j.humimm.2015.06.008. Epub 2015 Jun 11.


Association of antigen-specific T-cell responses with antigen expression and immunoparalysis in multiple myeloma.

Fichtner S, Hose D, Engelhardt M, Meißner T, Neuber B, Krasniqi F, Raab M, Schönland S, Ho AD, Goldschmidt H, Hundemer M.

Clin Cancer Res. 2015 Apr 1;21(7):1712-21. doi: 10.1158/1078-0432.CCR-14-1618. Epub 2015 Jan 21.


T cell-based targeted immunotherapies for patients with multiple myeloma.

Wang L, Jin N, Schmitt A, Greiner J, Malcherek G, Hundemer M, Mani J, Hose D, Raab MS, Ho AD, Chen BA, Goldschmidt H, Schmitt M.

Int J Cancer. 2015 Apr 15;136(8):1751-68. doi: 10.1002/ijc.29190. Epub 2014 Sep 19. Review.


Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.

Cheng J, Schmitt M, Wuchter P, Buss EC, Witzens-Harig M, Neben K, Hundemer M, Hillengass J, Alexi R, Goldschmidt H, Chen BA, Ho AD, Schmitt A.

Transfusion. 2015 Feb;55(2):275-83. doi: 10.1111/trf.12813. Epub 2014 Aug 13.


Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.

Hundemer M, Engelhardt M, Bruckner T, Kraeker S, Schmitt A, Sauer S, Neben K, Witzens-Harig M, Goldschmidt H, Ho AD, Wuchter P.

J Clin Apher. 2014 Dec;29(6):299-304. doi: 10.1002/jca.21323. Epub 2014 Apr 26.


Visceral leishmaniasis in a patient with relapsed multiple myeloma receiving high-dose melphalan and autologous stem cell transplant.

Radujkovic A, Hundemer M, Eisenbach C, Luft T, Penzel R, Goldschmidt H, Ho AD, Bellos F.

Leuk Lymphoma. 2014 Dec;55(12):2967-9. doi: 10.3109/10428194.2014.911862. Epub 2014 Jun 16. No abstract available.


Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents.

Merz M, Neben K, Raab MS, Sauer S, Egerer G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, Goldschmidt H, Hillengass J.

Ann Oncol. 2014 Jan;25(1):189-95. doi: 10.1093/annonc/mdt509.


[Acute dyspnea, subfebrile temperatures and chills in a patient with multiple myeloma].

Merz M, Herth I, Brandt J, Hundemer M, Neben K, Goldschmidt H, Heußel CP.

Med Klin Intensivmed Notfmed. 2014 Mar;109(2):137-40. doi: 10.1007/s00063-013-0298-z. Epub 2013 Oct 23. German. No abstract available.


Cytotoxicity of tumor antigen specific human T cells is unimpaired by arginine depletion.

Munder M, Engelhardt M, Knies D, Medenhoff S, Wabnitz G, Luckner-Minden C, Feldmeyer N, Voss RH, Kropf P, Müller I, Conradi R, Samstag Y, Theobald M, Ho AD, Goldschmidt H, Hundemer M.

PLoS One. 2013 May 23;8(5):e63521. doi: 10.1371/journal.pone.0063521. Print 2013.


Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia.

Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T.

J Clin Oncol. 2013 Jul 1;31(19):e300-3. doi: 10.1200/JCO.2012.45.9495. Epub 2013 May 20. No abstract available.


[Mild bleeding diathesis in a 62-year-old woman with hereditary thrombocytopenia].

Ventz R, Hundemer M, Witzens-Harig M, Lehmann B, Felbor U, Najm J.

Internist (Berl). 2013 Jun;54(6):765-8. doi: 10.1007/s00108-013-3284-x. German.


Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.

Witzens-Harig M, Hose D, Jünger S, Pfirschke C, Khandelwal N, Umansky L, Seckinger A, Conrad H, Brackertz B, Rème T, Gueckel B, Meißner T, Hundemer M, Ho AD, Rossi JF, Neben K, Bernhard H, Goldschmidt H, Klein B, Beckhove P.

Blood. 2013 May 30;121(22):4493-503. doi: 10.1182/blood-2012-05-429415. Epub 2013 Apr 19.


Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.

Herth I, Witzens-Harig M, Beckhove P, Hose D, Meissner T, Neuber B, Engelhardt M, Haas J, Neben K, Ho AD, Klein B, Goldschmidt H, Hundemer M.

Exp Hematol. 2013 Mar;41(3):231-40. doi: 10.1016/j.exphem.2012.10.018. Epub 2012 Nov 8.


Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma.

Neuber B, Herth I, Tolliver C, Schoenland S, Hegenbart U, Hose D, Witzens-Harig M, Ho AD, Goldschmidt H, Klein B, Hundemer M.

J Immunol. 2011 Jul 15;187(2):1047-56. doi: 10.4049/jimmunol.1002460. Epub 2011 Jun 15.


Monoclonal gammopathy and smoldering multiple myeloma: diagnosis, staging, prognosis, management.

Hillengass J, Moehler T, Hundemer M.

Recent Results Cancer Res. 2011;183:113-31. doi: 10.1007/978-3-540-85772-3_6. Review.


Charcot-Leyden crystals and bone marrow necrosis in acute myeloid leukemia.

Radujkovic A, Bellos F, Andrulis M, Ho AD, Hundemer M.

Eur J Haematol. 2011 May;86(5):451-2. doi: 10.1111/j.1600-0609.2011.01594.x. Epub 2011 Mar 30. No abstract available.


Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Seckinger A, Meissner T, Moreaux J, Goldschmidt H, Fuhler GM, Benner A, Hundemer M, Rème T, Shaughnessy JD Jr, Barlogie B, Bertsch U, Hillengass J, Ho AD, Pantesco V, Jauch A, De Vos J, Rossi JF, Möhler T, Klein B, Hose D.

Oncogene. 2009 Nov 5;28(44):3866-79. doi: 10.1038/onc.2009.257. Epub 2009 Aug 31.


Gene expression profiling and real-time PCR analyses identify novel potential cancer-testis antigens in multiple myeloma.

Condomines M, Hose D, Rème T, Requirand G, Hundemer M, Schoenhals M, Goldschmidt H, Klein B.

J Immunol. 2009 Jul 15;183(2):832-40. doi: 10.4049/jimmunol.0803298. Epub 2009 Jun 19.


Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.

Christensen O, Lupu A, Schmidt S, Condomines M, Belle S, Maier A, Hose D, Neuber B, Moos M, Kleist C, Terness P, Ho AD, Goldschmidt H, Klein B, Hundemer M.

J Immunother. 2009 Jul-Aug;32(6):613-21. doi: 10.1097/CJI.0b013e3181a95198.


Induction of angiogenesis by normal and malignant plasma cells.

Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, Mahtouk K, Hillengass J, Rème T, De Vos J, Hundemer M, Condomines M, Bertsch U, Rossi JF, Jauch A, Klein B, Möhler T.

Blood. 2009 Jul 2;114(1):128-43. doi: 10.1182/blood-2008-10-184226. Epub 2009 Mar 18.


The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.

Sprynski AC, Hose D, Caillot L, Réme T, Shaughnessy JD Jr, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B.

Blood. 2009 May 7;113(19):4614-26. doi: 10.1182/blood-2008-07-170464. Epub 2009 Feb 18.


Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.

Hose D, Rème T, Meissner T, Moreaux J, Seckinger A, Lewis J, Benes V, Benner A, Hundemer M, Hielscher T, Shaughnessy JD Jr, Barlogie B, Neben K, Krämer A, Hillengass J, Bertsch U, Jauch A, De Vos J, Rossi JF, Möhler T, Blake J, Zimmermann J, Klein B, Goldschmidt H.

Blood. 2009 Apr 30;113(18):4331-40. doi: 10.1182/blood-2008-09-178350. Epub 2009 Jan 26.


Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.

Klein U, Kosely F, Hillengass J, Hundemer M, Schmitt S, Neben K, Moehler T, Hegenbart U, Ho AD, Goldschmidt H.

Ann Hematol. 2009 Jan;88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31.


Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma.

Frank C, Hundemer M, Ho AD, Goldschmidt H, Witzens-Harig M.

Leuk Lymphoma. 2008 Apr;49(4):779-85. doi: 10.1080/10428190801911688.


Identification of HLA-A2 restricted T-cell epitopes within the conserved region of the immunoglobulin G heavy-chain in patients with multiple myeloma.

Belle S, Han F, Condomines M, Christensen O, Witzens-Harig M, Kasper B, Kleist C, Terness P, Moos M, Cremer F, Hose D, Ho AD, Goldschmidt H, Klein B, Hundemer M.

Eur J Haematol. 2008 Jul;81(1):26-35. doi: 10.1111/j.1600-0609.2008.01076.x. Epub 2008 Mar 19.


Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).

Hundemer M, Klein U, Hose D, Raab MS, Cremer FW, Jauch A, Benner A, Heiss C, Moos M, Ho AD, Goldschmidt H.

Bone Marrow Transplant. 2007 Dec;40(11):1033-7. Epub 2007 Sep 24.


TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.

Moreaux J, Hose D, Jourdan M, Reme T, Hundemer M, Moos M, Robert N, Moine P, De Vos J, Goldschmidt H, Klein B.

Haematologica. 2007 Jun;92(6):803-11.


Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.

Mahtouk K, Hose D, Raynaud P, Hundemer M, Jourdan M, Jourdan E, Pantesco V, Baudard M, De Vos J, Larroque M, Moehler T, Rossi JF, Rème T, Goldschmidt H, Klein B.

Blood. 2007 Jun 1;109(11):4914-23. Epub 2007 Mar 5.


Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B.

J Immunol. 2007 Mar 1;178(5):3307-15.


The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.

Raab MS, Breitkreutz I, Hundemer M, Benner A, Klaus J, Hegenbart U, Moehler T, Ho AD, Zeier M, Goldschmidt H.

Haematologica. 2006 Nov;91(11):1555-8.


CD200 is a new prognostic factor in multiple myeloma.

Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, Möhler T, De Vos J, Rossi JF, Goldschmidt H, Klein B.

Blood. 2006 Dec 15;108(13):4194-7. Epub 2006 Aug 31. Erratum in: Blood. 2007 Apr 1;109(7):2717.


Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

Hundemer M, Schmidt S, Condomines M, Lupu A, Hose D, Moos M, Cremer F, Kleist C, Terness P, Belle S, Ho AD, Goldschmidt H, Klein B, Christensen O.

Exp Hematol. 2006 Apr;34(4):486-96.

Supplemental Content

Loading ...
Support Center